Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
RANI Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Rani Therapeutics Holdings, Inc.NASDAQ: RANI
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $6.51M (cash outflow) fell 20.6% year over year, ahead of the -50.5% change in trailing-twelve-month free cash flow. Over 3 fiscal years it compounded at -26.9% a year.
Context
- Free cash flow amounted to 1151.4% of revenue in FY2025, down 2327.6 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -20.6% holds above the trailing-twelve-month pace of -50.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (18.8M) USD
- Year-over-year change
- +47.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (18.8M) | +47.4% |
| FY2024 | 2024-12-31 | (35.76M) | +31.8% |
| FY2023 | 2023-12-31 | (52.47M) | -9.0% |
| FY2022 | 2022-12-31 | (48.13M) | -47.0% |
| FY2021 | 2021-12-31 | (32.75M) | — |
Free Cash Flow vs competitors
How RANI compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.5% is the lowest of 9, against a peer median of +48.8%.
- Free cash flow amounts to 540.0% of revenue for RANI, versus a peer median of 1823.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $132.65M USD | +121.3% | -11.0% | 755.6% | |
| LTM Mar 2026 | $90.46M USD | +101.5% | -26.4% | 261.8% | |
| LTM Mar 2026 | $73.65M USD | +46.6% | +19.8% | — | |
| LTM Mar 2026 | CHF 54.13M CHF | -8.4% | — | — | |
| LTM Mar 2026 | $51.23M USD | +51.1% | -2.2% | 2871.8% | |
| FY2025 | €50.81M EUR | +597.2% | +35.8% | 1823.0% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $38.49M USD | +9.5% | +17.4% | — |
| LTM Mar 2026 | $37.46M USD | -12.4% | +3.0% | 7135.4% | |
| LTM Mar 2026 | $17.11M USD | -50.5% | -26.9% | 540.0% | |
| Peer median (excluding RANI) | — | +48.8% | +3.0% | 1823.0% | |
Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.33M) | (63.34M) | (33.97M) | (56.58M) | (29.67M) |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.6M | 15.78M | 19.01M | 16.03M | 11.8M |
| Change in Working Capital | (3.43M) | 509K | (2.14M) | (544K) | 6.96M |
| Accounts Receivables | 0 | 0 | 0 | (428K) | (1.61M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 543K | 163K | (595K) | 711K | (1.05M) |
| Other Working Capital | (3.97M) | 346K | (1.55M) | (827K) | 9.62M |
| Other Non-Cash Items | (43.58M) | (10K) | (34.96M) | 4.57M | (8.7M) |
| Operating Cash Flow | (32.25M) | (46.52M) | (51.24M) | (35.5M) | (18.71M) |
| Capital Expenditures | (506K) | (1.62M) | (1.23M) | (268K) | (88K) |
| Acquisitions (Net) | 0 | (851K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (73.82M) | (73.26M) | (58.72M) | (33.97M) |
| Sales of Investments | 0 | 3M | 104.35M | 77.55M | 26.75M |
| Other Investing Activities | 0 | 851K | 0 | 1.25M | 278K |
| Investing Cash Flow | (506K) | (72.44M) | 29.86M | 19.81M | (7.03M) |
| Debt Repayment | (2.85M) | 29.57M | 0 | (5M) | (20.72M) |
| Common Stock Issued | 73.65M | 317K | 395K | 18.63M | 61.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 26K | (886K) | (162K) | (47K) | (59K) |
| Financing Cash Flow | 77.15M | 29.01M | 233K | 13.59M | 40.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 44.4M | (89.95M) | (21.14M) | (2.1M) | 14.56M |
| Free Cash Flow | (32.75M) | (48.13M) | (52.47M) | (35.76M) | (18.8M) |
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.